FDA Awards Priority Review Voucher to Sarepta Therapeutics for Rare Pediatric Disease Product VYONDYS 53

Summary

The FDA has issued a priority review voucher to Sarepta Therapeutics, Inc. for its rare pediatric disease product VYONDYS 53, following a review of the product's eligibility under the FD&C Act and FDASIA.